Loading
Trials and products still moving through development for a cancer: recruiting, active or recently completed studies and the drugs they test. 3,134 records carry it: 2,334 trials, 800 drugs.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer NCT05607004 A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting. | HR-positive / HER2-negative breast cancer, High-risk early HR-positive breast cancer | none | none | ||
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma NCT04252859 A phase 2 trial of FES PET in Breast cancer, run by University of Utah, recorded as terminated on the registry. | Breast cancer | none | |||
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications NCT07432633 A phase 1/2 trial of [18F]FPyQCP in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting. | Colorectal cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer | none | none | ||
[225Ac]Ac-ETN029 ETN029 [225Ac]Ac-ETN029 is an experimental radioligand therapy from Mariana Oncology, in phase 1 trials for small cell lung cancer, large cell neuroendocrine carcinoma of the lung and neuroendocrine prostate cancer and other cancers. | Phase 1 | Small-cell lung cancer, Large cell neuroendocrine carcinoma of the lung, Prostate cancer | none | none | |
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications NCT07702292 A phase 2 trial of [68Ga]BED003 in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting. | Colorectal cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer | none | none | ||
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors NCT05619016 A phase 2 trial of HER2 PET in Breast cancer and HER2-positive gastric cancer, run by Karolinska University Hospital, with a status the registry has not verified recently. | Breast cancer, HER2-positive gastric cancer | none | none | ||
[Ac-225]RTX-2358 RTX-2358 [Ac-225]RTX-2358 is an experimental small-molecule radioligand therapy from Ratio Therapeutics, in phase 1 trials for FAP-positive soft tissue sarcoma and FAP-positive metastatic non-small cell lung cancer. | Phase 1 | Sarcomas, Non-small-cell lung cancer | none | none | |
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer NCT00450619 A phase 2 trial of Samarium-153 lexidronam and Sargramostim in Prostate cancer, run by National Cancer Institute (NCI), completed. | Prostate cancer | none | |||
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 A phase 1/2 trial of 177Lu-BetaBart in prostate cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, cervical cancer and endometrial cancer, run by Radiopharm Theranostics, Ltd, now recruiting. | Prostate cancer, Colorectal cancer, Non-small-cell lung cancer | none | none | ||
177Lu-FAP-VG11 177Lu-FAP-VG11 177Lu-FAP-VG11 is an experimental radioactive medicine from VitsGen Therapeutics that targets FAP, a protein on the support cells around many tumours. It is in an early hospital-led trial in China, and the FDA has given it orphan drug status for soft tissue sarcoma. | Sarcomas | none | orphan-designation | ||
18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy NCT05479136 A phase 3 trial of Fluciclovine F-18 in Glioma & glioblastoma, run by Nicole Hill, with a status the registry has not verified recently. | Glioma & glioblastoma | none | none | ||
18F-fluoroestradiol (FES) PET/CT for Breast Cancer NCT04883814 A phase 2 trial of FES PET in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently. | Breast cancer | none | none | ||
225Ac/64Cu-PD-29875 (Claudin 18.2) PD-29875 225Ac/64Cu-PD-29875 (Claudin 18.2) is an experimental radioligand peptide-drug conjugate from PeptiDream, in preclinical development for gastric cancer. | Preclinical | none | none | none | |
225Ac/64Cu-PD-32766 (CA9 theranostic pair) PD-32766 225Ac/64Cu-PD-32766 (CA9 theranostic pair) is an experimental radioligand peptide-drug conjugate, theranostic pair from PeptiDream, in phase 1 trials for clear cell renal cell carcinoma. | Phase 1 | Clear cell renal cell carcinoma | none | none | |
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma NCT00943449 A phase 2 trial of Resminostat and Sorafenib in Hepatocellular carcinoma, run by 4SC AG, completed. | Hepatocellular carcinoma, Advanced hepatocellular carcinoma | none | none | ||
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer NCT06298916 A phase 1/2 trial of 64Cu-LNTH-1363S in sarcomas, oesophageal cancer, gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Lantheus Medical Imaging, now recruiting. | Sarcomas, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer | none | none | ||
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) NCT04868604 A phase 1/2 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting. | Prostate cancer, Metastatic castration-resistant prostate cancer | none | none | ||
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer NCT06970847 A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting. | Prostate cancer, Biochemical recurrence of prostate cancer | none | none | ||
68Ga-DOTA-TATE PET/CT Imaging in NETs NCT04847505 A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently. | Neuroendocrine tumours | none | none | ||
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study NCT03849118 A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed. | Clear cell renal cell carcinoma | none | none | ||
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427 A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting. | Bladder & urothelial cancer, Muscle-invasive and advanced bladder cancer | none | none | ||
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer NCT07314723 A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting. | Bladder & urothelial cancer | none | none | ||
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer NCT06079112 A phase 1/2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting. | Bladder & urothelial cancer, Muscle-invasive and advanced bladder cancer | none | none | ||
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer NCT06592326 A phase 3 trial of Toripalimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting. | Bladder & urothelial cancer, Muscle-invasive and advanced bladder cancer | none | none | ||
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors NCT04632108 A phase 1/2 trial of ASKB589 Injection in advanced solid tumours, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active and no longer recruiting. | Metastatic cancer | none | none | ||
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H.. NCT00923481 A phase 2 trial of Fostamatinib in Head and neck squamous cell carcinoma and Pheochromocytoma and paraganglioma, run by National Cancer Institute (NCI), completed. | Head and neck squamous cell carcinoma, Pheochromocytoma and paraganglioma | none | none | ||
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04776330 A phase 1/2 trial of BCMA targeted prime CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting. | Multiple myeloma, Relapsed or refractory multiple myeloma | none | none | ||
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors NCT06341114 A phase 1/2 trial of BAT8008 injection in advanced solid tumours, run by Bio-Thera Solutions, active and no longer recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT06492005 A phase 2 trial of 9MW2821 in triple-negative breast cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting. | Triple-negative breast cancer, Metastatic triple-negative breast cancer | none | none | ||
A Clinical Study of Arfolitixorin in Patients With mCRC NCT06922383 A phase 1/2 trial of Arfolitixorin in colorectal cancer, run by Isofol Medical AB, now recruiting. | Colorectal cancer | none | none | ||
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111 A phase 2 trial of Calderasib and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer NCT06296706 A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting. | Gastric & gastro-oesophageal junction cancer | none | none | ||
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer NCT06974929 A phase 1/2 trial of HRS-6209 Capsules in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects NCT07446153 A phase 1/2 trial of HRS-8364 Tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT05923008 A phase 1/2 trial of IBI130 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272 A phase 1/2 trial of Docetaxel, Ifinatamab deruxtecan, Opevesostat and Enzalutamide in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting. | Prostate cancer, Metastatic castration-resistant prostate cancer | none | none | ||
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) NCT06833073 A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting. | Bladder & urothelial cancer, Non-muscle-invasive bladder cancer | none | none | ||
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) NCT06305767 A phase 1/2 trial of Pembrolizumab, Intismeran autogene and Enfortumab vedotin in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting. | Bladder & urothelial cancer, Muscle-invasive and advanced bladder cancer | none | none | ||
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer NCT07446387 A phase 2 trial of Iparomlimab and tuvonralimab in Colorectal cancer, run by Jiangsu Cancer Institute & Hospital, not yet recruiting. | Colorectal cancer | none | none | ||
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors NCT06208410 A phase 1/2 trial of JS105, Fulvestrant, Dalpiciclib, Toripalimab, Pyrotinib and Capecitabine in advanced solid tumours, run by Risen (Suzhou) Pharma Tech Co., Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) NCT07103018 A phase 1 trial of KTX-2001 run by K36 Therapeutics, Inc., now recruiting. | Metastatic castration-resistant prostate cancer | none | none | ||
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms NCT06398444 A phase 2/3 trial of Lutetium[177Lu] Oxodotreotide Injection in neuroendocrine tumours, run by Sinotau Pharmaceutical Group, now recruiting. | Neuroendocrine tumours | none | none | ||
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) NCT05579132 A phase 1/2 trial of MK-1045 in acute lymphoblastic leukaemia, run by MSD R&D (China) Co., Ltd., now recruiting. | Acute lymphoblastic leukaemia | none | none | ||
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) NCT07286149 A phase 1/2 trial of Calderasib, Patritumab deruxtecan, Sacituzumab tirumotecan and Cetuximab in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488 A phase 1/2 trial of MK-3120 in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting. | Bladder & urothelial cancer, Non-muscle-invasive bladder cancer | none | none | ||
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807 A phase 3 trial of Patritumab deruxtecan, Capecitabine, Doxorubicin and Trastuzumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors NCT06431243 A phase 1/2 trial of Purinostat in advanced solid tumours, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) NCT06637423 A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting. | Bladder & urothelial cancer, Non-muscle-invasive bladder cancer | none | none | ||
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting. | Triple-negative breast cancer, Early triple-negative breast cancer | none | none | ||
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors NCT06643754 A phase 1/2 trial of SHR-3276 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031 A phase 2 trial of Trastuzumab rezetecan, Adebrelimab and SHR-8068 in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting. | Biliary tract cancer | none | none | ||
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. NCT06434597 A phase 2 trial of SPH5030 in colorectal cancer, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting. | Colorectal cancer, HER2-amplified colorectal cancer | none | none | ||
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer NCT07597629 A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors NCT06214143 A phase 1/2 trial of T3011 high dose in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of YL205 in Patients With Advanced Solid Tumors NCT06459973 A phase 1/2 trial of intravenous (IV) infusion in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) NCT06890884 A phase 2 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and Polatuzumab vedotin in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting. | Diffuse large B-cell lymphoma | none | none | ||
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) NCT06962267 A phase 2 trial of TQB2916 Injection in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting. | Pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma | none | none | ||
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. NCT07672236 A phase 3 trial of BupiZenge 25 mg in advanced solid tumours, run by OncoZenge AB, now recruiting. | Metastatic cancer | none | none | ||
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients NCT05787613 A phase 2 trial of HLX26 and Serplulimab in non-small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting. | Non-small-cell lung cancer | none | none | ||
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma NCT06566586 A phase 2 trial of TQB3702 tablets+Chemotherapy regimen in non-Hodgkin lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting. | Non-Hodgkin lymphoma | none | none |
The table above loads 60 of 3,134 records first and fetches the rest as you scroll, search or filter. This tag as JSON · table rows · API